| Methods |
2‐arm active‐controlled randomised trial |
| Participants |
150 women were randomised in a hospital setting in Egypt. The population comprised women of unspecified parity, a singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised women with risk factors for PPH: duration of labour less than 2 hours or prolonged labour more than 24 hours, MgSO4 for pre‐eclampsia, chorioamnionitis, multiple pregnancy, previous PPH, APH and episiotomy. |
| Interventions |
200 mcg of ergometrine administered by an IV bolus versus 250 mcg of carboprost administered IM |
| Outcomes |
The study recorded the following outcomes: blood loss (mL); third stage duration (minutes); diarrhoea; nausea; vomiting; abdominal pain. |
| Notes |
Contact with study authors for additional information: no. Additional data from authors: no |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Table of random numbers was used. |
| Allocation concealment (selection bias) |
Unclear risk |
Allocation concealment was not reported. |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Blinding (of study participants and caregivers) was unclear. |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Assessor blinding was not reported. |
| Objective assessment of blood loss |
Low risk |
Blood was collected in a tray and measured. Sterile pads were placed over the vulva before and after use for a period of 4 hours. |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
The study authors did not mention any incomplete outcome data. |
| Selective reporting (reporting bias) |
Unclear risk |
The protocol of the study was unavailable for verification. |
| Intention to treat analysis |
Unclear risk |
The authors did not specify whether all those who were enrolled and randomly allocated to treatment were included in the analysis, in the groups to which they were randomised. |
| Funding source |
Unclear risk |
Carboprost kindly supplied by Prof. S. Bergstrom, Sweden but source(s) of funding for the study were not reported. |
